Publications by authors named "Emile Voest"

Claim this Profile
C
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.
Karlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman, Emile E Voest

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.
Pedro B Tan, Yara L Verschoor, José G van den Berg, Sara Balduzzi, Niels F M Kok, Emile E Voest

Nature· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strength through diversity: how cancers thrive when clones cooperate.
Marije C Kuiken, Maartje Witsen, Emile E Voest, Krijn K Dijkstra

Mol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subclonal immune evasion in non-small cell lung cancer.
Krijn K Dijkstra, Roberto Vendramin, Despoina Karagianni, Maartje Witsen, Felipe Gálvez-Cancino, Emile E Voest

Cancer Cell· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol.
Ilse A C Spiekman, Niven Mehra, Laurien J Zeverijn, Birgit S Geurts, Karlijn Verkerk, Emile E Voest

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microbial metabolic pathways guide response to immune checkpoint blockade therapy.
Iris L Mimpen, Thomas W Battaglia, Miguel Parra Martinez, Catherine Toner-Bartelds, Laurien J Zeverijn, Emile E Voest

Cancer Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman, Emile E Voest

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Base editing screens define the genetic landscape of cancer drug resistance mechanisms.
Matthew A Coelho, Magdalena E Strauss, Alex Watterson, Sarah Cooper, Shriram Bhosle, Emile E Voest

Nat Genet· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, Jade M van Berge Henegouwen, Gijs F de Wit, Emile E Voest

Clin Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
Birgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek, Jade M van Berge Henegouwen, Louisa R Hoes, Emile E Voest

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.
Jade M van Berge Henegouwen, Laurien J Zeverijn, Birgit S Geurts, Louisa R Hoes, Hanneke van der Wijngaart, Emile E Voest

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells.
Gabriele Picco, Yanhua Rao, Angham Al Saedi, Yang Lee, Sara F Vieira, Emile E Voest

Cancer Discov· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
Birgit S Geurts, Laurien J Zeverijn, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, Louisa R Hoes, Emile E Voest

J Pathol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agnostic drug development revisited.
Alberto Hernando-Calvo, Alice Rossi, Maria Vieito, Emile Voest, Elena Garralda

Cancer Treat Rev· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.
Myriam Chalabi, Yara L Verschoor, Pedro Batista Tan, Sara Balduzzi, Anja U Van Lent, Emile E Voest

N Engl J Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
Ilse A C Spiekman, Birgit S Geurts, Laurien J Zeverijn, Gijs F de Wit, Vincent van der Noort, Emile E Voest

Oncologist· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Yara L Verschoor, Joris van de Haar, José G van den Berg, Johanna W van Sandick, Liudmila L Kodach, Emile E Voest

Nat Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Ilse A C Spiekman, Laurien J Zeverijn, Birgit S Geurts, Karlijn Verkerk, Soemeya F Haj Mohammad, Emile E Voest

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Lindsay V M Leek, Jessica C L Notohardjo, Karlijn de Joode, Eline L Velker, John B A G Haanen, Emile E Voest

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).
Soemeya F Haj Mohammad, Hans J L Timmer, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman, Emile E Voest

Acta Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Kjetil Taskén, Soemeya F Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Emile E Voest

Acta Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.
Joris van de Haar, Joanne M Mankor, Karlijn Hummelink, Kim Monkhorst, Egbert F Smit, Emile E Voest

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pan-cancer analysis of the microbiome in metastatic cancer.
Thomas W Battaglia, Iris L Mimpen, Joleen J H Traets, Arne van Hoeck, Laurien J Zeverijn, Emile Voest

Cell· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.
Kris G Samsom, Linda J W Bosch, Luuk J Schipper, Daoin Schout, Paul Roepman, Emile E Voest

Nat Protoc· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Yara L Verschoor, Joris van de Haar, José G van den Berg, Johanna W van Sandick, Liudmila L Kodach, Emile E Voest

Nat Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis